Projects per year
Personal profile
Biography
Dr Ing Soo Tiong is a clinical haematologist consulting from Eastern Haematology Oncology Group.
He graduated from the University of Otago and completed his Basic Physician Training in Dunedin, New Zealand. He joined Alfred Hospital (2016) as the Leukaemia Fellow, awarded the HSANZ New Investigator Scholarship for 2017, and completed Haematology Advance Training in 2017 with dual Fellowships of the Royal Australasian College of Physicians and the Royal College of Pathologists of Australasia.
He is undertaking a part-time research higher degree at Alfred Hospital/Monash University. His interests are myeloid malignancies (acute leukaemias, myelodysplastic syndromes and myeloproliferative neoplasms), but would welcome any malignant and non-malignant haematological condition. He is also active in clinical trial developments, working to translate scientific breakthroughs and seek treatment options for patients he treats.
Ing-Soo is the medical lead for Acute Lymphoblastic Leukaemia at the Austin Hospital.
Other appointments: Alfred Hospital (Clinical Haematologist), Peter MacCallum Cancer Centre (Laboratory Haematologist).
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Research area keywords
- Haematology
- Myeloid malignancies
- Acute leukaemia
- Myelodysplasia
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
A Phase 1b, multicenter, open-label platform study of select drug combinations in adult patients with lower risk (very low, low, or intermediate risk) myelodysplastic syndrome
Tiong, I. S. (Primary Chief Investigator (PCI)), Teh, T.-C. (Primary Chief Investigator (PCI)) & Kennedy, N. (Project Manager)
1/04/21 → 31/12/25
Project: Research
-
A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) versus Epoetin Alfa for the Treatment of Anemia due to IPSS-R Very Low, Low or Intermediate Risk Myelodysplastic Syndromes (MDS) in ESA Naive Subjects who require Red Blood Cell Transfusions.
Teh, T.-C. (Primary Chief Investigator (PCI)), Tiong, I. S. (Primary Chief Investigator (PCI)) & Kennedy, N. (Chief Investigator (CI))
15/07/19 → 3/12/26
Project: Research
-
A Phase 2/3, Multicenter, Randomized, Dose Optimization (Part I), Double-blind (Part II) Study to Compare the Efficacy and Safety of Oral Azacitidine (Oral-Aza, ONUREG®) plus Best Supportice Care (BSC) versus Placebo plus BSC in Participants with IPSS-R Low- or Intermediate-risk Myelodysplastic (MDS)
Tiong, I. S. (Primary Chief Investigator (PCI)) & Malherbe, M. (Project Manager)
9/03/23 → 9/03/25
Project: Research
-
A Single-arm, open-label, Phase II study of sabatolimab in combination with azacitidine and venetoclax in adult participants with high or very high risk myelodysplastic syndrome (MDS) as per IPSS-R criteria
Tiong, I. S. (Primary Chief Investigator (PCI)) & Kennedy, N. (Project Manager)
28/05/21 → 31/12/23
Project: Research
-
A phase 2 study of venetoclax in combination with low-dose cytarabine in relapsing acute myeloid leukemia.
Wei, A. (Primary Chief Investigator (PCI)), Tiong, I. S. (Chief Investigator (CI)), Reynolds, J. (Associate Investigator (AI)) & Kennedy, N. (Chief Investigator (CI))
22/09/19 → 31/12/24
Project: Research
-
Tranexamic acid versus placebo to prevent bleeding in patients with haematological malignancies and severe thrombocytopenia (TREATT): a randomised, double-blind, parallel, phase 3 superiority trial
TREATT Trial Investigators, Jan 2025, In: The Lancet Haematology. 12, 1, p. e14-e22 9 p.Research output: Contribution to journal › Article › Research › peer-review
Open AccessFile3 Citations (Scopus) -
How comparable are patient outcomes in the “real-world” with populations studied in pivotal AML trials?
Tiong, I. S., Wall, M., Bajel, A., Kalro, A., Fleming, S., Roberts, A. W., Thiagarajah, N., Chua, C. C., Latimer, M., Yeung, D., Marlton, P., Johnston, A., Enjeti, A., Fong, C. Y., Cull, G., Larsen, S., Kennedy, G., Schwarer, A., Kipp, D. & Ramanathan, S. & 19 others, , 26 Mar 2024, In: Blood Cancer Journal. 14, 11 p., 54.Research output: Contribution to journal › Article › Research › peer-review
Open Access3 Citations (Scopus) -
Low-intensity venetoclax-based salvage as a bridge to allogeneic stem cell transplant in patients with acute myeloid leukemia failing conventional intensive chemotherapy
Ashby, M., Fleming, S., Teh, T. C., Tiong, I. S., Inam, S., Curtis, D. J., Patil, S., Vassili, C. & Chua, C. C., Jan 2024, In: Leukemia Research. 136, 4 p., 107429.Research output: Contribution to journal › Letter › Research › peer-review
1 Citation (Scopus) -
Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trial
Porta, M. G. D., Garcia-Manero, G., Santini, V., Zeidan, A. M., Komrokji, R. S., Shortt, J., Valcárcel, D., Jonasova, A., Dimicoli-Salazar, S., Tiong, I. S., Lin, C. C., Li, J., Zhang, J., Pilot, R., Kreitz, S., Pozharskaya, V., Keeperman, K. L., Rose, S., Prebet, T. & Lai, Y. & 5 others, , Sept 2024, In: The Lancet Haematology. 11, 9, p. e646-e658 13 p.Research output: Contribution to journal › Article › Research › peer-review
11 Citations (Scopus) -
Targeting Molecular Measurable Residual Disease and Low-Blast Relapse in AML With Venetoclax and Low-Dose Cytarabine: A Prospective Phase II Study (VALDAC)
Tiong, I. S., Hiwase, D. K., Abro, E., Bajel, A., Palfreyman, E., Beligaswatte, A., Reynolds, J., Anstee, N., Nguyen, T., Loo, S., Chua, C. C., Ashby, M., Wiltshire, K. M., Fleming, S., Fong, C. Y., Teh, T. C., Blombery, P., Dillon, R., Ivey, A. & Wei, A. H., 20 Jun 2024, In: Journal of Clinical Oncology. 42, 18, p. 2161-2173 13 p.Research output: Contribution to journal › Article › Research › peer-review
Open Access15 Citations (Scopus)